As filed with the Securities and Exchange Commission on March 21, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Cue Biopharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
| 47-3324577 |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
|
| |
40 Guest Street Boston, MA |
| 02135 |
(Address of principal executive offices) |
| (Zip Code) |
2016 Omnibus Incentive Plan, as amended
(Full title of the plan)
Daniel R. Passeri
Chief Executive Officer
Cue Biopharma, Inc.
40 Guest Street
Boston, MA 02135
(Name and address of agent for service)
(617) 949-2680
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ |
|
|
|
| |||
Non-accelerated filer |
| ☒ |
| Smaller reporting company |
| ☒ |
|
|
|
| |||
|
|
|
| Emerging growth company |
| ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Statement of Incorporation by Reference
This Registration Statement on Form S-8, relating to the 2016 Omnibus Incentive Plan, as amended (the “2016 Plan”), of Cue Biopharma, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-224018, relating to the 2016 Plan filed by the Registrant with the Securities and Exchange Commission on March 29, 2018, the contents of the Registration Statement on Form S-8, File No. 333-230282, relating to the 2016 Plan filed by the Registrant with the Securities and Exchange Commission on March 14, 2019, the contents of the Registration Statement on Form S-8, File No. 333-237140, relating to the 2016 Plan filed by the Registrant with the Securities and Exchange Commission on March 12, 2020, the contents of the Registration Statement on Form S-8, File No. 333-254045, relating to the 2016 Plan filed by the Registrant with the Securities and Exchange Commission on March 9, 2021 and the contents of the Registration Statement on Form S-8, File No. 333-263624, relating to the 2016 Plan filed by the Registrant with the Securities and Exchange Commission on March 16, 2022.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. | Exhibits. |
The following exhibits are incorporated herein by reference:
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 21st day of March, 2023.
|
|
|
CUE BIOPHARMA, INC. | ||
|
| |
By: |
| /s/ Daniel R. Passeri |
|
| Daniel R. Passeri |
|
| Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Cue Biopharma, Inc., hereby severally constitute and appoint Daniel R. Passeri, Kerri-Ann Millar and Colin Sandercock, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Cue Biopharma, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
| Title |
| Date |
|
|
| ||
/s/ Daniel R. Passeri Daniel R. Passeri |
| Chief Executive Officer and Director (Principal executive officer) |
| March 21, 2023 |
|
|
| ||
/s/ Kerri-Ann Millar Kerri-Ann Millar |
| Chief Financial Officer (Principal financial and accounting officer) |
| March 21, 2023 |
|
|
| ||
/s/ Frederick Driscoll Frederick Driscoll |
| Director |
| March 21, 2023 |
|
|
| ||
/s/ Aaron Fletcher Aaron Fletcher |
| Director |
| March 21, 2023 |
|
|
|
|
|
/s/ Tamar Howson |
| Director |
| March 21, 2023 |
Tamar Howson |
|
|
| |
|
|
|
|
|
/s/ Peter Kiener |
| Director |
| March 21, 2023 |
Peter Kiener |
|
|
| |
|
|
|
|
|
/s/ Frank Morich |
| Director |
| March 21, 2023 |
Frank Morich |
|
|
| |
|
|
|
|
|
